Bak Polyclonal Antibody BT-AP00831
Specifications
| 20ul / 50ul / 100ul |
Background:
The protein encoded by BAK1 belongs to the BCL2 protein family. BCL2 family members form oligomers or heterodimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. This protein (BCL2 antagonist/killer 1) localizes to mitochondria, and functions to induce apoptosis. It interacts with and accelerates the opening of the mitochondrial voltage-dependent anion channel, which leads to a loss in membrane potential and the release of cytochrome c. This protein also interacts with the tumor suppressor P53 after exposure to cell stress.
Classification:
Primary antibody
Alternative names:
BAK1; BAK; BCL2L7; CDN1; Bcl-2 homologous antagonist/killer; Apoptosis regulator BAK; Bcl-2-like protein 7; Bcl2-L-7
Species reactivity:
Human;Mouse
Host:
Rabbit
Isotype:
IgG
Immunogen:
The antiserum was produced against synthesized peptide derived from human Bak. AA range:1-50
Concentration:
1 mg/ml
Molecular weight:
23409
Applications:
WB, IHC-p, IF, ELISA
Storage:
-20°C for one year
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com
Fine Biotech is an ISO9001:2008 Certified Company,offers a full line of quality research kits,which include ELISA Kits,related ELISA assistant reagents and more high quality antibodies, recombinant proteins. Fine Biotech technical support are delicated to providing with professional and friendly assistance for our customers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality,rapid turnaround and personal support for all FineTest services are guaranteed. Should you have any problems,or any ideas on ways that we can improve our service,please feel free to call upon us.Thank you for your interest in FineTest products and we look forward to supplying you in the near future.